elobixibat profile

elobixibat: inhibits ileal bile acid transporter [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9939892
CHEMBL ID	3039515
SCHEMBL ID	1183501
MeSH ID	M0585116

Synonym
A3309 ,
A-3309 ,
865uek4ejc ,
glycine, (2r)-n-(2-((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy)acetyl)-2-phenylglycyl-
439087-18-0
a 3309
elobixibat
azd 7806
elobixibat [usan:inn]
unii-865uek4ejc
azd-7806
azd7806
CHEMBL3039515
SCHEMBL1183501
((2r)-2-(2-((3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1h-1.lambda.6,5-benzothiazepin-8-yl)oxy)acetamido)-2-phenylacetamido)acetic acid
glycine, (2r)-n-(((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy)acetyl)-2-phenylglycyl-
elobixibat [usan]
elobixibat [inn]
elobixibat [who-dd]
elobixibat [mi]
elobixibat (usan/inn)
D10796
DTXSID00195985
HY-15790
CS-0009139
DB12486
Q5367035
bdbm77088
us9694018, 14
2-[[(2r)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydrobenzo[b][1,4]thiazepin-8-yl)oxy]acetyl]amino]-2-phenylacetyl]amino]acetic acid
2-[[(2r)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-phenylacetyl]amino]acetic acid
goofice
ajg533
gtpl9996
(r)-2-(2-(2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetamido)-2-phenylacetamido)acetic acid
(r)-(2-(2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetamido)-2-phenylacetyl)glycine
MS-31154
EX-A5983
AKOS040741691

Excerpt	Reference	Relevance
"Elobixibat is a locally acting inhibitor of the ileal bile acid transporter. "	( Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation. Camilleri, M; Gillberg, PG; Hasunuma, T; Ishizaki, S; Kurosu, S; Matsuda, K; Mattsson, JP; Nakajima, A; Taniguchi, S, 2022)	2.57
"Elobixibat is a new laxative, but its efficacy and adverse events (AEs) are insufficiently examined compared with those of other laxatives. "	( Real-World Comparison of Elobixibat and Lubiprostone Treatment in Patients with Chronic Constipation: A Propensity Score-Matched Analysis. Amioka, S; Eguchi, T; Fujinami, M; Ikeoka, S; Inoue, K; Katayama, N; Matsuda, T; Matsumoto, M; Momose, K; Morisawa, T; Noda, M; Nonaka, T; Okada, A; Sako, T; Takagi, M; Yamaguchi, T; Yoshizaki, T, 2021)	2.37
"Elobixibat is a beneficial drug for patients with mildly symptomatic CC and is safe to use, given its few AEs."	( Real-World Comparison of Elobixibat and Lubiprostone Treatment in Patients with Chronic Constipation: A Propensity Score-Matched Analysis. Amioka, S; Eguchi, T; Fujinami, M; Ikeoka, S; Inoue, K; Katayama, N; Matsuda, T; Matsumoto, M; Momose, K; Morisawa, T; Noda, M; Nonaka, T; Okada, A; Sako, T; Takagi, M; Yamaguchi, T; Yoshizaki, T, 2021)	2.37
"Elobixibat is a novel ileal bile acid transport inhibitor that has demonstrated efficacy in proof of concept studies in experimental animals as well as phase 1, 2 and 3 trials in humans. "	( Review article: Elobixibat: a novel treatment for chronic constipation. Camilleri, M; Khanna, L, 2021)	2.41
"Elobixibat is a novel ileal bile acid transporter inhibitor. "	( Efficacy of elobixibat as bowel preparation agent for colonoscopy: Prospective, randomized, multi-center study. Akutagawa, T; Esaki, M; Hidaka, H; Jubashi, A; Kawakubo, H; Matsunaga, T; Miyahara, K; Noda, T; Ogata, S; Sakata, Y; Shimoda, R; Takamori, A; Takeuchi, Y; Tanaka, Y; Tominaga, N; Tsunada, S; Tsuruoka, N; Yamaguchi, D, 2022)	2.54
"Elobixibat is a novel inhibitor of the ileal bile acid transporter that is used to treat chronic constipation by stimulating bowel function."	( Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake. Fuyuki, A; Higurashi, T; Honda, Y; Ichikawa, Y; Ishiki, H; Iwaki, M; Kasai, Y; Kessoku, T; Kobayashi, N; Kobayashi, T; Nakajima, A; Okubo, N; Oyamada, S; Ozaki, A; Taguri, M; Takeda, Y; Yoshihara, T, 2021)	2.79
"Elobixibat is an oral treatment candidate for chronic constipation with a novel mechanism of action via inhibition of the ileal bile acid transporter. "	( Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. Nakajima, A; Seki, M; Taniguchi, S, 2018)	2.19
"Elobixibat is a minimally absorbed ileal bile acid transporter inhibitor. "	( Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial. Amano, H; Furuie, H; Kumagai, Y; Maeda, M; Nakagawa, C; Oikawa, I; Sasaki, Y, 2018)	2.19
"Elobixibat is a novel small-molecule that acts as an inhibitor of the ileal bile acid transporter (IBAT), and used for chronic constipation in Japan. "	( [Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE Ikeda, N; Seki, M; Taniguchi, S, )	1.79
"Elobixibat is a minimally absorbed ileal bile acid (BA) transporter (IBAT) inhibitor in development against chronic constipation (CC) and constipation-predominant Irritable Bowel Syndrome (IBS-C). "	( Specific inhibition of bile acid transport alters plasma lipids and GLP-1. Camilleri, M; Graffner, H; Holst, JJ; Rikner, L; Rudling, M, 2015)	1.86

Excerpt	Reference	Relevance
"Elobixibat treatment increased fecal total and primary bile acids and decreased levels of fecal lithocholic acid and serum total as well as secondary bile acids in patients with chronic constipation."	( Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation. Camilleri, M; Gillberg, PG; Hasunuma, T; Ishizaki, S; Kurosu, S; Matsuda, K; Mattsson, JP; Nakajima, A; Taniguchi, S, 2022)	1.85
"Elobixibat treatment increased fecal bile acid excretion and reduced serum bile acid concentrations."	( Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation. Camilleri, M; Gillberg, PG; Hasunuma, T; Ishizaki, S; Kurosu, S; Matsuda, K; Mattsson, JP; Nakajima, A; Taniguchi, S, 2022)	1.85
"Elobixibat is an oral treatment candidate for chronic constipation with a novel mechanism of action via inhibition of the ileal bile acid transporter. "	( Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. Nakajima, A; Seki, M; Taniguchi, S, 2018)	2.19
"Elobixibat as a treatment of CIC appears promising."	( Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation. Miner, PB, 2018)	2.64
"Treatment with elobixibat reduced the serum BA and increased the fecal BA concentration, and ameliorated the liver inflammation and fibrosis."	( Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice. Fukuda, H; Higashi, T; Hirai, F; Kawashima, M; Kitaguchi, T; Morihara, D; Nagata, T; Sakisaka, S; Shakado, S; Takata, K; Takedatsu, H; Takeyama, Y; Tanaka, T; Tsuchiya, N; Uchida, Y; Yamauchi, E; Yamauchi, R; Yokoyama, K, 2021)	2.4

Excerpt	Reference	Relevance
" The primary outcome of the 52-week open-label trial was safety (type, severity, and incidence of adverse drug reactions) at all times from treatment initiation."	( Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Camilleri, M; Gillberg, PG; Mattsson, JP; Nakajima, A; Ohta, A; Seki, M; Taniguchi, S, 2018)	0.79
" 163 (48%) patients in the 52-week trial had an adverse drug reaction, the most common of which were mild gastrointestinal disorders (in 135 [40%] patients)."	( Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Camilleri, M; Gillberg, PG; Mattsson, JP; Nakajima, A; Ohta, A; Seki, M; Taniguchi, S, 2018)	0.79
"Non-alcoholic fatty liver disease (NAFLD) pathogenesis involves abnormal metabolism of cholesterol and hepatic accumulation of toxic free-cholesterol."	( Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. Honda, Y; Imajo, K; Iwaki, M; Kessoku, T; Kobayashi, T; Nakajima, A; Ogawa, Y; Ozaki, A; Saigusa, Y; Saito, S; Usuda, H; Wada, K; Yamamoto, K; Yamanaka, T; Yoneda, M, 2020)	0.75
" This proof-of-concept study will determine whether the combination therapy of EXB and CTM is effective and safe for patients with NAFLD."	( Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. Honda, Y; Imajo, K; Iwaki, M; Kessoku, T; Kobayashi, T; Nakajima, A; Ogawa, Y; Ozaki, A; Saigusa, Y; Saito, S; Usuda, H; Wada, K; Yamamoto, K; Yamanaka, T; Yoneda, M, 2020)	0.75
"We aimed to discuss and compare reported adverse reactions and drug add-ons associated with elobixibat and lubiprostone use in chronic constipation treatment, as the safety of these drugs has not been well examined in post-marketing clinical settings."	( Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study. Kawakami, E; Kimura, M; Miyazaki, C; Nagamura, M; Ooba, N; Sato, T; Shimada, M; Takahashi, M; Takahashi, Y; Tokuyoshi, J; Ushida, M, 2021)	1.24
"Safety information will be collected as adverse events, specifically focusing on those occurring in association with study conduct."	( Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group stud (CONST-PD). Eguchi, H; Fukae, J; Fuse, A; Hatano, T; Hattori, N; Kamo, H; Kano, M; Kurita, N; Nakajima, A; Nakajima, S; Nakamura, R; Nishikawa, N; Nishioka, K; Ogaki, K; Ogawa, T; Oji, Y; Oyama, G; Saiki, S; Shimo, Y; Takeshige-Amano, H; Taniguchi, D; Tsunemi, T; Yanagisawa, N, 2022)	0.99

Excerpt	Reference	Relevance
" In this randomised, double-blind, placebo-controlled, parallel-group, phase IIa study, we aim to provide a proof-of-concept assessment by evaluating the efficacy and safety of EXB in combination with CTM in patients with NAFLD."	( Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. Honda, Y; Imajo, K; Iwaki, M; Kessoku, T; Kobayashi, T; Nakajima, A; Ogawa, Y; Ozaki, A; Saigusa, Y; Saito, S; Usuda, H; Wada, K; Yamamoto, K; Yamanaka, T; Yoneda, M, 2020)	0.75

Excerpt	Relevance	Reference
" In a phase II study with chronic constipation, the recommended dosage for oral administration of elobixibat once daily was estimated to be 10 mg."	( [Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE Ikeda, N; Seki, M; Taniguchi, S, )	0.56

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	15 (44.12)	24.3611
2020's	19 (55.88)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	9 (25.71%)	5.53%
Reviews	8 (22.86%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	2 (5.71%)	0.25%
Other	16 (45.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	4.13	2	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
7 alpha-hydroxy-4-cholesten-3-one 7 alpha-hydroxy-4-cholesten-3-one: structure. 7alpha-hydroxycholest-4-en-3-one : A cholestanoid consisting of a cholesterol core having an oxo group at the 3-position, a C=C bond at the 4,5-position and an alpha-hydroxy group at the 7-position.	6.51	3	3	3-oxo-Delta(4) steroid; 7alpha-hydroxy steroid; cholestanoid	human metabolite; mouse metabolite
lubiprostone [no description available]	4.01	3	0
deoxycholic acid Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.	8.64	1	1	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human blood serum metabolite
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	3.19	1	0
obeticholic acid obeticholic acid: A farnesoid X receptor agonist and anticholestatic agent that is used in the treatment of chronic liver diseases; structure in first source.. obeticholic acid : A dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatment of primary biliary cholangitis.	3.19	1	0	3alpha-hydroxy steroid; 7alpha-hydroxy steroid; dihydroxy-5beta-cholanic acid	farnesoid X receptor agonist; hepatoprotective agent
prucalopride prucalopride: a 5-HT4 agonist enterokinetic compound	3.19	1	0	benzamides
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	3.18	1	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
methylnaltrexone methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer	3.18	1	0	phenanthrenes
alvimopan anhydrous alvimopan: mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain	3.18	1	0	peptide
glucagon-like peptide 1 Glucagon-Like Peptide 1: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.	5.85	2	2
piperidines Piperidines: A family of hexahydropyridines.	3.18	1	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	3.8	1	1	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
plecanatide plecanatide: A uroguanylin analog and guanylate cyclase (GC-C receptor) agonist that activates receptors on gut epithelial cells to maintain barrier function, mucus production, and suppress inflammation. It is used in the treatment of chronic idiopathic constipation and other gastrointestinal disorders.	3.19	1	0
cholestyramine resin Cholestyramine Resin: A strongly basic anion exchange resin whose main constituent is polystyrene trimethylbenzylammonium Cl(-) anion.	3.68	2	0

Condition	Indicated	Relationship Strength	Studies	Trials
Colonic Inertia Symptom characterized by the passage of stool once a week or less.	0	13.87	32	14
Idiopathic Parkinson Disease [description not available]	0	3.8	1	1
Constipation Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.	1	15.87	32	14
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	0	3.8	1	1
Complications of Diabetes Mellitus [description not available]	0	2.41	1	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	0	2.41	1	0
Fatty Liver, Nonalcoholic [description not available]	0	4.22	4	0
Cancer of Liver [description not available]	0	2.6	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	2.6	1	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	1	11.22	4	0
Atherogenesis [description not available]	0	2.6	1	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	0	2.6	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.82	2	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	0	2.6	1	0
Chronic Illness [description not available]	0	11.62	15	10
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	11.62	15	10
Benign Neoplasms [description not available]	0	2.31	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.31	1	0
Colitis, Mucous [description not available]	0	5.58	3	1
Irritable Bowel Syndrome A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.	0	5.58	3	1
Cholera Infantum [description not available]	0	8.68	5	4
Colicky Pain [description not available]	0	7.6	4	4
Abdominal Pain Sensation of discomfort, distress, or agony in the abdominal region.	0	7.6	4	4
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	3.01	1	0
Dyslipidemia [description not available]	0	7.54	4	4
Dyslipidemias Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.	0	7.54	4	4
Anorectal Diseases [description not available]	0	3	1	0
Colonic Diverticulosis [description not available]	0	3	1	0
Rectal Diseases Pathological developments in the RECTUM region of the large intestine (INTESTINE, LARGE).	0	3	1	0

elobixibat

Description

Cross-References

Synonyms (39)

Research Excerpts

Overview

Treatment

Toxicity

Compound-Compound Interactions

Dosage Studied

Research

Studies (34)

Market Indicators

Research Demand Index: 49.30

Study Types

elobixibat

Description

Cross-References

Synonyms (39)

Research Excerpts

Overview

Treatment

Toxicity

Compound-Compound Interactions

Dosage Studied

Research

Studies (34)

Market Indicators

Research Demand Index: 49.30

Study Types

Related Drugs (15)

Related Conditions (29)